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A series of cinnamic acid conjugates of primaquine and chloroquine were evaluated for their in vitro antileishmanial activities.
Although primaquine derivatives hadmodest activity, chloroquine conjugates exhibited potent activity against both promasti-
gotes (50% inhibitory concentration [IC50] 2.6 to 21.8M) and intramacrophagic amastigotes (IC50 1.2 to 9.3M) of Leish-
mania infantum. Both the high activity of these chloroquine analogues and their mild-to-low toxicity toward host cells make
them promising leads for the discovery of new antileishmanial agents.
Leishmania parasites maintain their life cycle by alternating be-tween promastigotes in the gut of phlebotomine insects and
amastigotes insidemacrophages ofmammalian hosts (1, 2). These
protozoa cause leishmaniasis, a complex of mammalian diseases
whose clinical symptoms range from self-healing cutaneous le-
sions to the more severe visceralizing infection (3). Human vis-
ceral leishmaniasis (VL) results from infection with L. donovani
andL. infantum and is usually fatal if left untreated, accounting for
more than 50,000 deaths per year (4, 5). The management of VL
relies mainly on chemotherapy with pentavalent antimonials,
pentamidine, paromomycin, amphotericin B or its lipid formula-
tions, and miltefosine (5, 6). However, the treatment of this dis-
ease is hindered by the limited efficacy, high toxicity, reduced
bioavailability, high cost, and parasite resistance to the action of
several of the available drugs (7). As such, it is mandatory to de-
velop novel compounds devoid of these limitations. To respond to
those needs, we have tested the activity of cinnamic acid conju-
gates of the 8-aminoquinoline primaquine (PQ) and the 4-ami-
noquinoline chloroquine (CQ) against L. infantum. The rationale
for these tests was that (i) these conjugates have been recently
reported as interesting antimalarial leads (8–10) and (ii) PQ
(compound 1) and CQ (compound 3) have proven activity
against several protozoans, including visceralizing Leishmania
(11–15).
All the N-cinnamoylated aminoquinolines (compounds 2a to
2k and 5a to 5j) and compound 3b (CQ-C4 [see Table 2]; used as
the parent compound for the synthesis of 5a to 5j) were synthe-
sized as previously described (8, 10). Cinnamic acid (compound
4), PQ, CQ (Sigma-Aldrich, Spain), and miltefosine (Cayman
Chemicals) were commercially acquired. All test compounds and
the reference drugs PQ andmiltefosinewere dissolved in dimethyl
sulfoxide (Sigma), while CQ (sodium salt; Sigma)was dissolved in
phosphate-buffered saline (PBS). All solutions were stored at
20°C until use. Their antileishmanial activity was initially eval-
uated on the promastigote stage of L. infantum (MHOM/MA/67/
ITMAP-263, zymodeme MON-1; laboratory reference strain
[16]). Briefly, promastigotes (1 106/well) were cultured at 25°C
in complete RPMI medium (Gibco, Life Technologies) (13) sup-
plemented with the different compounds at concentrations be-
tween 0.63 and 80M.The antileishmanial activitywas assessed at
72 h of culture by the resazurin methodology, as previously re-
ported (13). All the 50% inhibitory concentration (IC50) (M)
values reported herein were determined with GraphPad Prism 5.0
software (GraphPad Software Inc.) from plots of percentages of
parasite growth in relation to control versus inhibitor concentra-
tions.
We found that PQ derivatives 2b to 2d and 2j (IC50 30 M)
were more active than PQ (IC50  33.5 M) and as active as
miltefosine (compound 6; IC50  19.6 M) against L. infantum
promastigotes (Table 1). These results indicate that the conjuga-
tion of PQ with a cinnamic acid containing a substituent of p-Me
(p-methyl), p-iPr (p-isopropyl), p-OMe, or m-NO2 (compound
2b, 2c, 2d, or 2j, respectively) in its aromatic ring moderately im-
proved the activity of PQ against the promastigote stage of L.
infantum. The insertion of any of the other substituents (com-
pounds 2a, 2e to 2i, and 2k) on the cinnamic acid ring did not
improve the antileishmanial activity of PQ.
Regarding the 4-aminoquinolines, when tested against L. in-
fantum promastigotes, CQ, CQ-C4, and most of the 5a to 5j ana-
logues had activities that were comparable to or higher than those
of PQ derivatives and miltefosine (Table 2). In particular, com-
pounds 5a and 5c to 5g were the most effective of the series, with
IC50 5.5 M.
Conjugate 5awas themost interesting compound of this series,
with an IC50 againstL. infantumpromastigotes of 3.1M,which is
6-fold lower than that of its parent 3b compound (IC50 18M).
In order to understand how the conjugation with cinnamic acid
improved the activity of 3b, we evaluated the activity of cinnamic
acid alone (compound 4) but found no significant activity against
this form of the parasite (IC50  80 M). Interestingly, the
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equimolar mixture of 3b and 4 also did not have higher activity
than 3b alone (IC50  18 M). Hence, activity displayed by the
conjugates is notmerely due to the sumof the intrinsic activities of
the respective building blocks but is due to the action of new
features generated by their covalent linkage.
It should be noted that none of conjugates 5a to 5j (IC50 2.6
M) was more active than CQ (IC50 1.3 M) against L. infan-
tum promastigotes. This could signify that the positively charged
tertiary amine in the aliphatic chain of CQ is important for activity
against the promastigote stage of L. infantum. In fact, the mild
TABLE 1 Antiparasitic activities of primaquine, its cinnamic acid derivatives, and the reference drug miltefosine, with estimated ClogP values
Compounda Rb
IC50 (M) for L. infantum promastigotes
at 72 h (mean SD) ClogP valuec
1 33.5 8.7 2.28
2a H 39.0 4.5 4.30
2b p-Me 18.3 1.3 4.68
2c p-iPr 16.0 3.0 5.46
2d p-OMe 22.3 1.8 4.23
2e m-F 52.9 17.4 4.46
2f p-F 35.7 11.2 4.47
2g p-Cl 35.1 6.3 5.04
2h p-Br 30.1 9.0 5.04
2i o-NO2 35.4 5.2 4.13
2j m-NO2 24.7 2.9 4.14
2k p-NO2 160 4.15
6 19.6 4.3 4.39
a 1, primaquine; 2a to 2k, cinnamic acid primaquine derivatives; 6, the reference drug miltefosine.
b R, cinnamic acid substituent. Me, methyl;i Pr, isopropyl.
c ClogP values were calculated using ALOGPS 2.1 (http://www.vcclab.org/lab/alogps/).
TABLE 2 Antiparasitic activities and macrophage toxicities of chloroquine, CQ-C4, cinnamic acid, cinnamic acid analogues of chloroquine, and the
reference drug miltefosine, with calculated selectivity indices and estimated ClogP valuesa
Compound Rb
IC50 (M) for L. infantum
promastigotes at 72 h
(mean SD)
IC50 (M) for L. infantum
intramacrophagic
amastigotes at 72 h
(mean SD)
IC50 (g/ml) for
L. infantum
intramacrophagic
amastigotes at 72
h (mean SD)
CC50 (M) for mouse
bone marrow-derived
macrophages at 72 h
(mean SD)
CC50 (g/ml) for
mouse bone marrow-
derived macrophages
at 72 h (mean SD) SI
ClogP
valuec
3a 1.3 0.2 23.0 12.1 11.9 6.2 71.3 2.7 36.8 1.4 3.1 4.42
3b 18.0 2.9 43.9 5.8 11.0 1.4 74.5 1.8 18.6 0.4 1.7 2.47
4 H 80.0 47.1 16.1 7.0 2.4 80.0 11.9 1.7 2.00
3b 4 H 18.0 5.0 65.5 34.5 34.1 16.9
5a H 3.1 1.8 1.2 0.8 0.5 0.3 25.4 6.7 9.6 2.5 21.2 4.49
5b p-Me 21.8 15.4 4.86
5c p-iPr 2.6 0.4 4.0 0.9 1.7 0.4 13.5 6.2 5.7 2.6 3.4 5.65
5d p-OMe 3.9 2.0 9.3 1.9 3.8 0.8 61.9 26.5 25.4 10.9 6.7 4.41
5e m-F 3.3 1.4 4.2 2.9 1.7 1.2 17.6 0.6 7.0 0.2 4.2 4.66
5f p-F 5.5 2.1 5.7 2.7 2.3 1.1 22.2 5.9 8.8 2.3 3.9 4.67
5g p-Cl 3.1 0.9 6.6 2.3 2.7 1.0 7.7 2.1 3.2 0.9 1.2 5.09
5h p-Br 10.8 1.6 5.23
5i o-NO2 7.3 0.4 4.37
5j m-NO2 21.0 7.2 4.38
6 19.6 4.3 4.1 3.3 1.7 1.3 25.5 4.5 10.4 1.8 6.2 4.39
a 3a, chloroquine; 3b, CQ-C4; 4, cinnamic acid; 5a to 5j, cinnamic acid analogues of chloroquine; 6, the reference drug miltefosine; SI, calculated selectivity indices.
b R, cinnamic acid substituent. Me, methyl;i Pr, isopropyl.
c ClogP was calculated using ALOGPS 2.1 (http://www.vcclab.org/lab/alogps/).
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basicity conferred to CQ by its tertiary amine has been considered
a key factor forCQ’s activity against themalaria agentPlasmodium
(17). However, we have recently shown that the same cinnamic
acid CQ conjugates described in this paper display nanomolar
activities against blood-stage malaria parasites (8, 9), suggesting
that the tertiary amine is not as important for CQ’s antimalarial
activity as previously supposed. What we suggest, instead, is that
the N-cinnamoylated conjugates exert their antimalarial activity
by a mechanism(s) of action (MOA) distinct from that of CQ. In
fact, (i) the conjugates’ ability to block hemozoin formation, the
MOA traditionally attributed to CQ (17), is not fully correlated
with their antimalarial activities (8, 9), and (ii) unlike CQ, the
conjugates are also significantly active against liver-stage plasmo-
dia (9). Alternatively, the decreased antipromastigote activity of
cinnamoyl conjugates may be related to stereoelectronic features
of the cinnamoyl group compared to those of the N,N-diethyl
moiety in CQ, eventually affecting the compound’s binding to its
target in the L. infantum promastigote.
Finally, no clear correlation between lipophilicity and activity
could be established among CQ analogues 5a to 5j or PQ deriva-
tives 2a to 2k (IC50 and ClogP values in Tables 1 and 2).
Given that CQ and its analogues 5a and 5c to 5g displayed
potent activity against promastigotes, we then explored their po-
tential against L. infantum intramacrophagic amastigotes. For that
purpose, differentiatedmacrophages (4 105/well), derived from
the bone marrow of BALB/c mice, were infected with stationary
promastigotes of L. infantum (4  106/well), as previously de-
scribed (13). Compounds were added after 24 h of infection at
concentrations between 2.5 and 40 M. Cells were fixed and
stained with Hemacolor (Merck, Germany) 72 h later. Represen-
tative pictures were obtained with an Olympus CX31 light micro-
scope equipped with a DP-25 camera (Imaging software CellBˆ,
Olympus). A minimum of 1,600 macrophages were counted per
experimental condition using the Cell Note software (18), and the
“parasite index” was calculated as the number of amastigotes per
100 macrophages. The IC50 (M) values were determined with
GraphPad software from plots of percentages of parasite growth
reduction in relation to control versus inhibitor concentration.
All tested CQ analogues (compounds 5a and 5c to 5g; IC50 
9.3 M) were more active than CQ (IC50  23.0 M) against
intramacrophagic amastigotes of L. infantum in the order
5a(H) ¡ 5c(p-iPr)  5e(m-F) ¡ 5f(p-F)  5g(p-Cl) ¡ 5d(p-
OMe), as shown in Table 2.Moreover, they presented activity that
was higher than or comparable to that of miltefosine (IC50 4.1
M). No clear correlation was found between the activity of CQ
and its conjugates against intramacrophagic amastigotes (Table 2)
and their lipophilicity (ClogP values) or electronic effects of sub-
stituents on the aromatic ring of the cinnamoyl moiety. Still, dif-
ferent explanations might account for the efficacy of CQ conju-
gates being higher than that of the parent CQ against amastigotes:
CQmight bemore promptlymetabolized by themacrophage into
a less effective compound, in this way explaining its reduced ac-
tivity toward amastigotes compared to promastigotes (Table 2).
Alternatively, amastigotes might have increased capacity to efflux
CQ, but not its cinnamic acid analogues, through, e.g., the previ-
ously characterized ABCG6 transporter of L. infantum (19).
Lastly, the cytotoxic properties of the conjugates, compared to
that of CQ, may also account for different activities against intra-
macrophagic parasites, as explained below.
We also evaluated the cytotoxicity of themost interesting com-
pounds, by the resazurin methodology (13). Macrophages (8 
104/well) were treatedwithCQand compounds 5a and 5c to 5g for
72 h at 37°C, in a concentration range of 0.63 to 100 M. The
concentrations that caused a 50% loss of host cell viability (CC50
[in M]) (Table 2) were determined with GraphPad software
from plots of percentages of viability in relation to the control
concentration relative to the inhibitor concentration. All cin-
namic acid analogues were more cytotoxic than the parent CQ
compound (CC50  71.3 M), which may also justify their in-
creased activity against intramacrophagic amastigotes. How-
ever, with the exception of compound 5g (CC50 7.7 M), no
CQ analogue was more toxic to macrophages (CC50  13.5
M) than the reference drug miltefosine (CC50  25.5 M).
The presence of p-Cl, unlike that of the other substituents, in
the aromatic ring of the cinnamic acid favors both antileishma-
nial activity and toxicity.
Interestingly, compound 5a, which had the best activity against
promastigotes, also exhibited high activity against L. infantum in-
tracellular amastigotes (IC50  0.5 g/ml) while maintaining a
relatively low toxicity to the host cells (CC50  9.6 g/ml, com-
parable to that of miltefosine) (Table 2). Actually, this compound
exhibits a selectivity index (SI  21.2) that is more than 3-fold
higher than that of the reference drug miltefosine (SI 6.2). This
means that compound 5a conforms to the World Health Organi-
zation’s criteria for hit identification against Leishmania intra-
macrophagic amastigotes, since it displays an IC50 1 to 2 g/ml
and a selectivity index (SI) 20 (20). Similarly to what happened
in promastigote cultures, cinnamic acid alone (compound 4) or
equimolar mixtures of compounds 4 and 3b had no significant
activity against L. infantum amastigotes, indicating that new mo-
lecular features generated by the covalent linkage of the two phar-
macophores were responsible for the antileishmania activity.
Overall, by conjugating the heteroaromatic core of CQ to sub-
stituted cinnamic acids, we have found five compounds with po-
tent activity against L. infantum and moderate toxicity toward
mammalian host cells. Therefore, they represent good candidates
for further development as antileishmanial agents.
Keeping in mind that the tested compounds were recently re-
ported as antimalarial leads, this work reinforces the notion that
common and/or related chemical scaffolds have the potential to
be active in multiple parasites, given the phylogenetic relatedness
of the target organisms. Studies on the possible mechanism(s)
underlying the antileishmanial activity displayed by the N-cin-
namoylated aminoquinolines will follow. As a recent work has
suggested that CQ may act against visceralizing Leishmania (11,
12, 19) by promoting the alkalinization of the parasite’s acidocal-
cisomes (21), a role of the antileishmanial lead 5a as such a pro-
moter will be investigated. Hopefully, this and subsequent work
will contribute to the development of new effective antiparasitic
agents and to the unveiling of their mode(s) of antiprotozoal ac-
tion.
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